/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial
Event: ESC Congress 2022
Topic: Aldosterone Antagonists
Session: Anticoagulant therapy: real world use and clinical challenges
Estimating the penetrance of genetic variants linked to cardiomyopathy
Event: Heart Failure 2022
Topic: Clinical
Session: Highlight on cardiomyopathy
ESC 365 is supported by
